<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825194/" ref="ordinalpos=3363&amp;ncbi_uid=5493457&amp;link_uid=PMC3825194" image-link="/pmc/articles/PMC3825194/figure/F004/" class="imagepopup">Fig. 4.TGF-β <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> inhibitors under development for potential cancer therapy. (blue line box) Antisense molecules inhibit TGF-β synthesis; (black line box) monoclonal antibodies, soluble receptors and anti-receptor monoclonal antibodies inhibit ligand-receptor interaction; (red line box) receptor kinase inhibitors and peptide aptamers (purple line box) inhibit signal transduction..  From: Targeting the Transforming Growth Factor-? <span class="highlight" style="background-color:">Signaling</span> in Cancer Therapy. </a></div><br /><div class="p4l_captionBody"></div></div>